A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers
Status:
Completed
Trial end date:
2010-06-28
Target enrollment:
Participant gender:
Summary
A study to determine the safety and tolerability of pazopanib eye drops. The study will also
determine how the drug is absorbed and metabolized over time. Repeat doses of eye drops will
be administered to healthy adult volunteers over a 14-day period with one additional dose
given on the 15th day of the session. Three groups of subjects may receive either active drug
or placebo (drops without drug). The first group of subjects will receive a maximum of 1.6mg
of pazopanib or placebo. The dose of drug to be given to the next two groups will be
determined based on the results of the first group of subjects. The last group of subjects
will be of Japanese descent.